Pulmonary alveolar microlithiasis: no longer in the stone age

Elisabeth Bendstrup ¹ and Åsa Lina M. Jönsson²

Affiliations: ¹Center for Rare Lung Diseases, Dept of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark. ²Dept of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.

Correspondence: Elisabeth Bendstrup, Center for Rare Lung Diseases, Dept of Respiratory Diseases and Allergy, Aarhus University Hospital, Palte Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark. E-mail: kabend@rm.dk

ABSTRACT Pulmonary alveolar microlithiasis (PAM) is a rare parenchymal lung disease caused by variants in the *SCL34A2* gene and characterised by the accumulation of intra-alveolar microliths. PAM has been reported in fewer than 1100 cases throughout the world. It is an autosomal recessive hereditary disease and often associated with consanguinity. Progress with respect to the genetic background and pathophysiology has resulted in an increased understanding of the disease in recent years. Until now, 30 genetic different *SCL34A2* variants have been reported, which all are considered significant for disease development. There is no sex difference and the majority of cases are diagnosed at the age of 30–40 years. Many patients are asymptomatic and the diagnosis is made at random. When symptomatic, dyspnoea, cough, chest pain and fatigue are common complaints. The diagnosis of PAM can confidently be based on typical radiographic findings and genetic testing proving rare biallelic *SCL34A2* gene variants. Bronchoalveolar lavage and histopathology may show microliths. There is no disease-specific treatment and management is supportive. Lung transplantation should be considered in advanced cases.

@ERSpublications

Pulmonary alveolar microlithiasis is a rare, autosomal recessive lung disease. Formation of alveolar microliths is caused by *SCL34A2* variants. The prognosis is severe; respiratory failure is common. Lung transplantation is the only effective therapy. <https://bit.ly/3dpkbRw>

Cite this article as: Bendstrup E, Jönsson ÅLM. Pulmonary alveolar microlithiasis: no longer in the stone age. *ERJ Open Res* 2020; 6: 00289-2020 [<https://doi.org/10.1183/23120541.00289-2020>].

Introduction

Pulmonary alveolar microlithiasis (PAM) is a rare autosomal recessive lung disease characterised by the accumulation of calcium phosphate deposits (calcospherites or microliths) in the alveoli despite normal serum calcium and phosphorus, and absence of any systemic disease of calcium metabolism [1]. PAM is often diagnosed coincidentally; patients are often asymptomatic until 30–40 years of age. The disease cause is variable. Prognosis may be good, but many patients will develop progressive disease with restrictive lung function impairment, dyspnoea and cough, hypoxia and respiratory failure, secondary pulmonary hypertension and ultimately death. Until today, nearly 1100 cases have been reported in the literature.

The first description of PAM is attributed to Italian biologist and physician, MALPIGHI [2], who in 1686 in his work “In vesiculis pulmonum innumeri lapilli sunt” describes that “the lungs were heavy and compact with patches of black countless small stones in the interior of the lungs”. In 1918, HARBITZ [3] diagnosed the first case in Norway as an autosomal, recessive disease with extensive intra-alveolar microliths on autopsy called Harbitz syndrome and in 1933, PUHR [4] renamed the disease as PAM. In recent years, studies have unveiled the genetic background of PAM, resulting in an improved understanding of the disease, which will hopefully in the future result in better treatment options.

Epidemiology

Until today, a little fewer than 1100 cases of PAM have been reported since HARBITZ [3] published the first case in 1918. The majority of patients reported are from Asia and Europe. Turkey, China, Japan, India, Italy and the United States have reported the majority of cases, with the highest number of cases in people of Turkish and Italian descent [5]. Two clusters have been reported, one in Italy and another in Turkey. However, patients with PAM have been identified worldwide [6].

PAM affects both sexes with a slight predominance in males (male/female ratio 0.56) [6]. Almost 40% of cases are diagnosed before the age of 20 years and almost 90% before 50 years, although PAM may be recognised later in life. PAM in children is also reported and a recent study found 28 cases with a median age at first symptoms of 22 months, equivalent to 2–3% of all PAM patients [5, 7–9]. Both sporadic and familial cases are published and a positive family history in some populations is reported in 37% of cases [6]. In families with PAM, the transmission is usually horizontal and if vertical transmission is present, this is exclusively due to consanguinity [6].

Genetic background and pathophysiology

The gene responsible for PAM has been mapped to 4p15.2 and identified as the *SLC34A2* gene (solute carrier family 34 member 2) (Entrez Gene ID 10568). *SLC34A2* has 13 exons, of which the first is noncoding and the longest transcript encodes a 690 amino acid protein, the sodium-dependent phosphate transport protein 2B (NaPi-2b) (NP_006415). NaPi-2b is expressed in human epithelial cells and in the lungs in alveolar type II cells [10–13].

NaPi-2b is presumed to play an important role in type II alveolar cells with regard to the cell uptake of phosphate from the alveolar fluid [14, 15]. Decreased activity or loss of function of the transporter due to *SLC34A2* variants may therefore lead to accumulation of phosphate in the alveolar lumen due to insufficient alveolar phosphate uptake. Excess of phosphate in the alveolar space may lead to phosphate precipitation with calcium in the extracellular fluid and formation of intra-alveolar calcium phosphate stones (*i.e.* microliths) [16, 17].

To date, 30 different *SLC34A2* variants in PAM have been reported in the literature and are located in most parts of the coding regions of the gene [18]. Variants include one or a few nucleotides or deletions involving either a single exon or several exons (table 1). In a recent report, 12 unrelated patients from several European countries and the United States have been reported with 10 different allelic variants in the *SLC34A2* gene. In addition, in a Turkish report, seven unrelated PAM patients were found with six different *SLC34A2* variants [18, 19]. In one of the patients, variants were present in a compound heterozygous state, whereas a homozygous-variant state was reported in the rest of the patients [18, 19].

Some authors have pointed out the relationship between the geographical origin and the variant localisation, with patients from China and Japan reported with variants in exon 8 [39]. In addition, the variant c.1402_1404delACC in exon 12 has so far only been reported in patients from Europe [18]. In a recent published cohort of patients, a correlation between phenotype and genotype severity was found [18]. However, it still remains to be investigated whether a genotype–phenotype correlation exists in PAM. Like many other rare autosomal recessive disorders, PAM is associated with consanguinity and a significant part of the patients have at least one sibling who is also affected by the disease [6].

TABLE 1 *SLC34A2* variants reported in pulmonary alveolar microlithiasis

Location	cDNA	Consequence	Number of patients	Reference
Homozygous allele state				
Exon 1	c.-6773_-6588del	NA	6	CORUT <i>et al.</i> 2006 [19]
Exon 2–6	~5.5 kb deletion	NA	1	ISHIHARA <i>et al.</i> 2009 [20]
Exon 3	c.114delA	Frameshift	2	CORUT <i>et al.</i> 2006 [19]
Exon 3	c.212_224del	Frameshift	1	VISMARA <i>et al.</i> 2015 [21]
Exon 3	c.226C>T	Nonsense	6	CORUT <i>et al.</i> 2006 [19] CAKIR <i>et al.</i> 2015 [22] MEHTA <i>et al.</i> 2016 [23]
Exon 4	c.316G>C	Substitution	2	CORUT <i>et al.</i> 2006 [19] OZBUDAK <i>et al.</i> 2012 [24]
Exon 5	c.380–345_c.523+659del	NA	2	DANDAN <i>et al.</i> 2018 [25]
Intron 5–Exon 6	c.524–18_559del	NA	1	SIMON <i>et al.</i> 2018 [26]
Exon 6	c.560G>A	Substitution	1	JÖNSSON <i>et al.</i> 2020 [18]
Exon 6	c.575C>A	Substitution	3	MA <i>et al.</i> 2014 [27]
Exon 6	c.593T>C	Substitution	3	GABER <i>et al.</i> 2012 [28]
Exon 7	c.646G>T	Nonsense	1	JÖNSSON <i>et al.</i> 2020 [18]
Exon 8	c.857_871delins19	Frameshift	2	HUQUN <i>et al.</i> 2007 [16]
Exon 8	c.893_897delTTGTC	Frameshift	1	ALASTAL 2017 [29]
Exon 8	c.906G>A	Nonsense	1	JÖNSSON <i>et al.</i> 2020 [18]
Exon 8	c.910A>T	Nonsense	6	YIN <i>et al.</i> 2013 [30] ZHONG <i>et al.</i> 2009 [31] ZHANG <i>et al.</i> 2017 [32]
Intron 9	c.1048+1G>A [#]	NA	4	HUQUN <i>et al.</i> 2007 [16]
Exon 10	c.1136G>A	Substitution	1	JÖNSSON <i>et al.</i> 2020 [18]
Exon 11	c.1238G>A	Nonsense	1	JÖNSSON <i>et al.</i> 2020 [18]
Exon 11	c.1327delC	Nonsense	2	JÖNSSON <i>et al.</i> 2020 [18]
Exon 11	c.1328delT	Frameshift	1	CORUT <i>et al.</i> 2006 [19]
Intron 11	c.1333+1G>A	NA	1	JÖNSSON <i>et al.</i> 2020 [18]
Exon 12	c.1342delG	Nonsense	1	CORUT <i>et al.</i> 2006 [19]
Exon 12	c.1342_1361del	Frameshift	1–2	ELLISON <i>et al.</i> 2009 [7] SIGUR <i>et al.</i> 2019 [33]
Exon 12	c.1390G>C	Substitution	2	JÖNSSON <i>et al.</i> 2020 [18]
Exon 12	c.1402_1404delACC	In-frame deletion	3	JÖNSSON <i>et al.</i> 2012 [18] JÖNSSON <i>et al.</i> 2020 [34]
Exon 12	c.1456C>T	Nonsense	1	PROESMANS <i>et al.</i> 2012 [35]
Exon 1–13	Whole gene deletion	NA	1	STOKMAN <i>et al.</i> 2016 [36]
Compound heterozygous allele state				
Exon 4	c.316G>A	Substitution	1	JÖNSSON <i>et al.</i> 2020 [18]
Exon 11	c.1238G>A	Nonsense		
Exon 8	c.910A>T	Nonsense	1	WANG <i>et al.</i> 2014 [37]
Exon 12	c.1363T>C	Substitution		
Intron 9	c.1048+1G>A	NA	1	Izumi <i>et al.</i> 2017 [38]
Exon 12	c.1390G>C	Substitution		

NA: not applicable. [#]: Originally reported as IVS8+1G>A. *SLC34A2* DNA reference sequence: Ensembl Transcript ID ENST00000382051.7 (GRCh38.p12 assembly).

Symptoms and clinical signs

PAM presents most commonly in the second and third decade of life but may be seen at any age [6, 18, 40]. Diagnosis is often made at a more advanced age, presumably because many cases are asymptomatic until then. PAM is a heterogeneous disease and clinical characteristics may range from asymptomatic to pronounced symptoms with right heart and respiratory failure. Disease progression is unpredictable with some patients remaining stable for many years. The clinical hallmark of the disease is the clinical–radiological dissociation, with extensive radiological involvement disproportionate to the subjective complaints, especially in the early phases of the disease [1].

When symptoms are present, the most common complaints are dyspnoea, dry cough, chest pain and fatigue, but also hypoxia, cyanosis, clubbing, haemoptysis, pneumothorax, weight loss and weakness are reported [1, 5, 6, 41]. The dry cough is believed to be caused by the stimulation of unmyelinated c fibres in the bronchial tree and lung parenchyma by microliths [42, 43].

The clinical appearance is often normal but upon progression, fatal respiratory or cardiac failure may develop with accompanying clinical features such as peripheral oedema, liver enlargement, tachypnoea and cyanosis [5, 6].

Extrapulmonary manifestations

Several patients have reported extrapulmonary calcifications such as medullary nephrolithiasis, calcifications in the lumbar sympathetic chain, prostate, aorta and mitral valves, pericardium, the gastric wall, testicles, punctuate calcifications in seminal vesicles and periurethral and epididymal calcifications [6, 18]. The extrapulmonary calcifications can cause symptoms in PAM such as infertility, haematuria and gallstone symptoms.

Some authors have suggested the usage of positron emission tomography (PET) for the identification of extrapulmonary involvement [44]. 18F sodium fluoride PET/computed tomography (CT) based on increased fluoride uptake in hydroxyapatite crystals (microliths), may be the preferred method as it has shown a higher uptake of radiotracer in the lungs, defining a larger extent of pathological involvement compared to 18F-fluoro-2-deoxyglucose (18F-FDG) PET/CT in two PAM patients [44, 45]. 18F-FDG PET/CT has thus been proposed as useful in evaluation of pulmonary inflammation grade. Low 18F-FDG uptake in the lungs has been reported in several patients and may represent a “burned out” inflammatory process [44–47]. Contrary to this, no significant inflammation was found at autopsy in a patient with a high uptake of 18F-FDG in the lungs [48].

PAM in children

Until 2019, 28 published cases of PAM in children younger 6 years of age including 7 infants under 2 years and 2 newborn premature twins have been reported [7]. The majority of the patients (65%) below 5 years of age originated from Asia and 25% of the cohort came from Turkey. The geographical origin and sex distribution were similar to the cohort from Castellana that included all ages of PAM [6, 7].

Symptoms in children with PAM were similar to symptoms in adult PAM patients but the children seem to be more symptomatic and to have more bronchitis and dry cough. Fever, which is not observed in adults, was observed in 30% of the children at presentation. Also contrary to adult patients, some of the children presented with acute respiratory failure [7]. Some speculate that early onset PAM may represent a more severe disease, potentially explained by promoting factors such as genetic and epigenetic factors. Also, environmental factors such as exposure to passive smoking and viral infections may be able to modify the course of the disease. Respiratory infections with cough and fever are common in children in this age group and it cannot be ruled out that PAM was fortuitously diagnosed in an early stage due to symptoms related to viral and other infections.

Three groups of PAM children with PAM might exist: one group with fortuitously identified PAM, another group diagnosed by family investigations and a third group representing a more severe disease.

CT findings in children are less typical compared to adults and show more diffuse lung involvement although patchy involvement has been also observed. Typical features are ground-glass opacities, septal thickening and bilateral micronodular densities and calcifications mostly present along the bronchovascular bundles, the interlobular septa and the subpleural area. Calcifications are frequent, but contrary to adults, are less severe and smaller and mainly restricted to the lower lobes. Ground-glass opacities that are rarely seen in adults were more common in the children younger than 6 years of age, and children never show signs of lung fibrosis [7].

Diagnosis

A diagnosis of PAM can confidently be based on typical radiographical findings and genetic testing proving rare biallelic *SCL34A2* gene variants. When genetic testing is unavailable or negative, a definite diagnosis can be established by bronchoalveolar lavage (BAL) or a lung biopsy, either bronchoscopic or surgical, with the demonstration of intra-alveolar microliths (figure 1). The decision to obtain tissue should preferably be taken at a multidisciplinary team discussion at experienced centres and individualised based on patients' individual risk and availability and experience of procedures at the centre. Transbronchial forceps biopsies generally results in smaller biopsies with crush artefacts whereas transbronchial cryobiopsies and surgical lung biopsies are larger with a higher diagnostic yield but also with a risk of more complications [49, 50].

Blood assays

Standard blood tests have no place in PAM diagnostics, as common biomarkers of bone metabolism in peripheral blood including, but not limited to calcium and phosphate, are normally not affected in PAM

FIGURE 1 Diagnostic algorithm for pulmonary alveolar microlithiasis. The algorithm is step-wise with the least invasive procedure preferred as the first choice. The decision to obtain tissue should always be individualised and preferably be taken at a multidisciplinary team discussion. Less experienced centres are recommended to consult an expert centre. #: intra-alveolar calcifications, micronodules, ground-glass opacities, thickened septa, subpleural cysts; ¶: if genetic analysis is not available, proceed to invasive examinations;+: transbronchial forceps or cryobiopsy; the choice between these should be based on availability and experience and considering the least invasive procedure first; if transbronchial biopsies are non-diagnostic, consider surgical lung biopsy.

[18, 40]. Blood tests for genetic analysis showing a variant in *SCL34A2* in homozygous state or two variants in compound heterozygous state will provide the diagnosis.

Surfactant protein (SP)-D, SP-A and monocyte chemotactic protein 1 (MCP-1) have all been suggested as useful serum biomarkers of disease activity but are not routinely used in most centres [17, 51, 52].

Sputum testing

Sputum examination for microliths has shown presence of microliths in older studies but is rarely used nowadays [53]. More contemporary, DNA extracted from sputum can be used for genetic analysis.

Lung function

Pulmonary function tests will most often present as normal in less advanced disease but as PAM progress a restrictive lung function impairment with reduced dynamic and static volumes and diffusion capacity will develop [18, 40].

Imaging

On chest radiography, PAM is characterised by a “sandstorm” appearance with diffuse distribution of innumerable small sand-like micronodules (also called microliths, calcipherites or calcospherites), within the air spaces, particularly in the lower parts of the lung. A black pleural sign or black pleural line is a common finding and describes the vertical strip of peripheral hyperlucency between the ribs and the adjacent diffusely dense calcified lung parenchyma and is caused by subpleural cystic changes. Often, the mediastinal contour and diaphragm cannot be identified due to intensive microliths and interstitial involvement in advanced disease [54] (figure 2).

High-resolution CT is regarded as the gold standard for PAM diagnosis and demonstrates numerous sandstorm-like calcifications throughout the lungs with subpleural and peribronchial distribution particularly affecting the basal segments and paracardiac region [54]. Typical features include intra-alveolar calcifications (microliths), micronodules, ground-glass opacities along with superimposed smooth thickened of the interlobular septa, subpleural microhoneycombing cystic changes, subpleural reticular

FIGURE 2 Chest radiography of two patients with pulmonary alveolar microlithiasis. a) Patient 1, 2003, radiological severity stage II. b) Patient 1, 2013, radiological severity stage III. c) Patient 1, 2019, radiological severity stage IV. d) Patient 2, 2007, radiological severity stage IV. White arrows demonstrate the “black pleural sign”.

thickening and, in some instances, a crazy paving pattern. Calcifications of the pleura also have been reported [54, 55] (figure 3).

Recently, four radiological severity stages have been proposed:

Stage 1: Microliths are few and the calcification grade is low. The stage is therefore known as the “pre-calcific phase” and is only rarely observed in asymptomatic children.

Stage 2: The typical “sandstorm” appearance is now present. The calcific micronodules (<1 mm in diameter) are seen scattered throughout the lungs with basal and mid-lung predominance. Some micronodules may be larger in diameter (~2–4 mm). The boundaries of the heart and diaphragm appear clear. Stage 2 is characteristic in childhood or adolescence.

Stage 3: In the third stage the micronodules disseminate, interstitial thickening is observed and the heart and diaphragm boundaries are obliterated. This phase is often seen in young adults.

Stage 4: This is the most advanced stage and is characterised by extensive interstitial calcification and sometimes involvement of the pleura giving the appearance of “white lungs”. Fibrosis, subpleural microcysts, areas of ossification and pneumothorax can be present. This stage is typically reported in older patients or in cases with advanced disease. This appearance is very characteristic and can in the right clinical context be sufficient for diagnosis [6].

FIGURE 3 High-resolution computed tomography of two patients with pulmonary alveolar microlithiasis. a) Patient 1, 2003, ground-glass opacities in apical lung fields and c) calcifications, micronodules, thickened septa in basal lung fields. b) Patient 1, 2016, calcifications with micronodules, thickened septa and cysts in apical lung fields and d) progression of calcifications with consolidations and crazy paving. e) Patient 2, 2005, radiological severity stage IV. Subpleural microcysts (black pleural sign), ground-glass opacities and micronodules in apical lung fields and f) same patient, basal lung fields showing extensive calcifications with thickened septa and micronodules.

Thoracic ultrasonography has gained increasing interest in recent years and increased thickening and irregularities of a hyper-echoic pleural line and millimetric echogenic foci with no marked acoustic shadowing in the subpleural and basal fields area has been described [41]. However, discrepancy of thoracic ultrasonography findings compared with conventional CT imaging limits its use so far [41, 56].

Histological features

Typical histopathological findings are best seen with trichrome staining and characterised by multiple intra-alveolar spherical calcium and phosphate deposits, the so-called calcospherites or microliths (figure 4). Microliths are composed of hydroxyapatite crystals that form concentric lamellae surrounding an amorphous central nucleus. The size is usually less than 1 mm, but occasionally larger microliths up to 5 mm are observed. Inflammation, fibrosis and calcification of the lung interstitium and pleura are also noticed. The histopathological findings of intra-alveolar microliths are most often very characteristic. In cases of less classical findings, consultation with an expert centre is recommended.

Analysis of BAL is often inconclusive but occasionally, mild lymphocytosis and microliths can be identified in BAL; microliths can occasionally be found in sputum samples [18, 34, 40, 57].

PAM clinical disease severity score

A clinical disease severity score has recently been proposed. The score is based upon a composite assessment of nine clinical parameters: pulmonary hypertension, dyspnoea, chest pain, fatigue, clinical progression, limitations of daily activities, incapability to work, forced vital capacity and diffusing capacity of the lung for carbon monoxide, and determines three severity grades: mild, moderate and severe [18]. The score needs still validation in other and prospective cohorts.

FIGURE 4 Lung section from a male patient with pulmonary alveolar microlithiasis showing calcified microliths in the intra-alveolar spaces. Haematoxylin and eosin staining. Original magnification: a) $\times 50$ and b) $\times 400$. Scale bars: a) 1 mm and b) 100 μm . By courtesy of pathologist Johanne Lade Keller, Dept of Pathology, Aarhus University Hospital, Aarhus, Denmark.

Differential diagnosis

On imaging, the differential diagnosis includes a number of diseases with a similar radiological appearance of micronodules, such as miliary tuberculosis, fungal infection, varicella pneumonia, sarcoidosis, amyloidosis, pulmonary alveolar proteinosis, pulmonary hemosiderosis, metastatic calcification in chronic renal failure and pneumoconiosis (e.g. silicosis, talcosis, stannosis, baritosis) [6, 58–60]. It is important to differentiate PAM from these diseases to ensure accurate treatment. However, while the radiological appearance of calcifications is more intense in patients with PAM, the symptoms of the other differential diagnoses are usually more severe.

Treatment

Currently, there is no approved medical or genetic treatment available to alter the progression of PAM and many therapies, including corticosteroids, calcium-binding agents and bronchoalveolar whole-lung lavage, have proven to be ineffective. The long-term prognosis is poor in some patients and lung transplantation is the only effective therapy to date.

Corticosteroids

Corticosteroids have been reported to result in symptom alleviation in a few patients with PAM but are in general considered noneffective [46, 61–63].

Sodium thiosulfate

Sodium thiosulfate is a calcium-chelating and solubilising agent that has been tried in a single patient with PAM. Despite treatment, disease progression was observed on chest CT [64].

Whole-lung lavage

As the microliths are located in the alveolus, repeated BAL has been suggested as a possible treatment strategy for PAM but it has so far been ineffective [39, 61, 65].

Low-phosphate diet

A low-phosphate diet in mice with a PAM phenotype has shown reduced formation of microliths but there are so far no human studies and a potential beneficial effect is thus unknown in PAM patients [17].

Bisphosphonates

Bisphosphonates inhibit bone resorption by attaching to hydroxyapatite binding sites in the bone and by interfering with the osteoclasts [66]. It has been speculated whether bisphosphonates could be beneficial in patients with PAM by preventing calcifications in the alveoli and hence the formation of microliths [66–68]. A total of 12 cases of patients with PAM treated with bisphosphonates have been published [23, 40, 42, 67–74]. The results are inconsistent as some patients responded with respect to clinical and radiological improvement, while others remained unaffected. Most patients (10) were treated with etidronate with a greatly varied dose (200 to 900 $\text{mg}\cdot\text{day}^{-1}$) and treatment duration (6 months to 11 years). Insufficient dosage, treatment duration and initiation of treatment in patients with advanced disease with well-formed microliths have been considered as possible explanations for treatment failure.

Supportive treatment

Patients with PAM who are hypoxemic should be prescribed supplemental oxygen therapy. Pneumococcal and influenza vaccinations should be offered to all PAM patients.

Lung transplantation

Lung transplantation, either single or bilateral, is usually considered in patients with end-stage lung disease. The optimal time for referring patients with PAM for lung transplant has not been defined but referral is recommended before the onset of severe right ventricular dysfunction [6].

So far, lung transplantation has been reported about 20 patients. Recently, ALROSSAIS *et al.* [75] reviewed 19 lung transplant patients with PAM. The mean age at transplantation was 47 years, with an average follow-up period of almost 3 years. Complications and survival seemed not to differ from those described in transplant recipients with other background lung diseases. Mortality was caused by bronchiolitis obliterans (n=2), sepsis (n=2), haemodynamic instability (n=1), and multi-organ failure (n=1) [75].

The longest survival continued follow-up beyond 15 years [76]. No recurrence of PAM has been observed during the post-transplant period.

Familial genetic counselling

Families with PAM should be offered genetic counselling to help them understand the implications of having a genetic disease. In addition, prenatal testing and pre-implantation genetic diagnosis for PAM may be offered to families at high risk for having a child with PAM.

Prognosis

The disease course of PAM is variable and there is lack of observations to inform the long-term prognosis [18]. However, case series suggest that the disease is slowly progressive with reduced survival. Some patients with PAM can remain stable and the longest reported follow-up period is 58 years [6]. If a diagnosis was made in childhood, there are a few reports with more than 40 years of follow-up [6]. A Japanese study of 53 patients with PAM found that 18 patients (34%) died due to PAM within a follow-up period of 10–49 years. The mean age at death was 46 years [77]. Similarly, others also report death to occur in the fifth decade of life, resulting from respiratory and right heart failure [6].

Environmental factors like smoking, inhalation of snuff, repetitive lung infections and cold weather may be associated with both the onset and the course of the disease but firm evidence is lacking and further investigations are warranted [19, 27, 35, 40, 76].

Future perspectives

PAM remains a challenge due to its rareness and limited treatment options. In recent years, our knowledge of clinical characteristics, risk factors, genetics, pathogenesis and diagnostic approaches has increased, but major gaps are still present. Still, it is case reports, case series and retrospective reviews that form our knowledge. Larger patient cohorts based on international collaborations as in the recent published paper by JÖNSSON *et al.* [18] or international patient registries are needed to collect cases, allow for biobanking and for execution of prospective studies. Characterisation of pathogenic mechanisms and possible genotype–phenotype correlations is essential to explore the relevance of different genetic variants in patients as is also identification of risk factors for disease progression and extrapulmonary involvement. Increased awareness and better access to genetic testing is warranted to avoid lung biopsies as these are inevitably associated to risk of complications. Biomarkers and predictive tools for disease progression and prognosis are needed to inform patients of their disease course and to decide when to initiate potential future effective treatment and to refer patients for lung transplant evaluation. Also, a disease severity score will be useful for evaluation of disease burden, stratification of patients and for research design. Ultimately, we need better treatment options. Increased knowledge of the functional deficits of different variants and discovery of the crystalline structure of NaPi-2b will be steps on this pathway.

Conclusion

PAM remains a rare disease with fewer than 1100 cases reported. It is an autosomal recessive disease and 30 allelic variants have been reported in around 60 cases. The types of variants are heterogeneous and located almost in all exons of the *SLC34A2* gene. The disease spectrum is variable and although a PAM disease severity score has been proposed, a validated genotype–phenotype correlation has to be proven. Until now, the treatment options are few and lung transplantation remains the only effective therapy. Increased knowledge of the genetic background will result in increased understanding of the pathophysiology of PAM and will hopefully result in new treatment options in the future.

Conflict of interest: E. Bendstrup has nothing to disclose. Å.L.M. Jönsson has nothing to disclose.

References

- 1 Francisco FA, Pereira e Silva JL, Hochegger B, *et al.* Pulmonary alveolar microlithiasis. State-of-the-art review. *Respir Med* 2013; 107: 1–9.

- 2 Anzalone M, ed. *Marcello Malpighi e i suoi scritti sugli organi del respirare. Manoscritto vol XII, foglio 81* Bologna, Tamari Editori, 1966: pp. 259–262.
- 3 Harbitz F. Extensive calcification of the lungs as a distinct disease. *Arch Intern Med* 1918; 21: 139–146.
- 4 Puhr I. Microlithiasis alveolaris pulmonum. *Virchows Arch A Patho Anat Histopathol* 1933; 290: 156.
- 5 Khaladkar SM, Kondapavuluri SK, Kamal A, et al. Pulmonary alveolar microlithiasis - clinico-radiological dissociation - A case report with radiological review. *J Radiol Case Rep* 2016; 10: 14–21.
- 6 Castellana G, Castellana G, Gentile M, et al. Pulmonary alveolar microlithiasis: review of the 1022 cases reported worldwide. *Eur Respir Rev* 2015; 24: 607–620.
- 7 Sigur E, Roditis L, Labouret G, et al. Pulmonary alveolar microlithiasis in children less than 5 years of age. *J Pediatr* 2020; 217: 158–164.
- 8 Zhang XD, Gao JM, Luo JM, et al. Pulmonary alveolar microlithiasis: a case report and review of the literature. *Exp Ther Med* 2018; 15: 831–837.
- 9 Stamatopoulos A, Patrini D, Mitsos S, et al. An unusual late onset of pulmonary alveolar microlithiasis: a case report and literature review. *Respir Med Case Rep* 2017; 22: 24–27.
- 10 National Center for Biotechnology Information. SLC34A2, Gene ID: 10568. Bethesda (MD): National Library of Medicine (US). www.ncbi.nlm.nih.gov/gene/ Date last accessed: 12 January, 2020. Date last updated: 15 June, 2020.
- 11 The UniProt Consortium. UniProt: the universal protein knowledgebase. *Nucleic Acids Res* 2017; 45: D158–D169.
- 12 Zerbino DR, Achuthan P, Akanni W, et al. Ensembl 2018 (Release 92). *Nucleic Acids Res* 2018; 46: D754–D761.
- 13 Yates B, Braschi B, Gray KA, et al. Genenames.org: the HGNC and VGNC resources in 2017. *Nucleic Acids Res* 2017; 45: D619–D625.
- 14 Traebert M, Hattenhauer O, Murer H, et al. Expression of type II Na-P(i) cotransporter in alveolar type II cells. *Am J Physiol* 1999; 277: L868–L873.
- 15 Poelma DL, Ju MR, Bakker SC, et al. A common pathway for the uptake of surfactant lipids by alveolar cells. *Am J Respir Cell Mol Biol* 2004; 30: 751–758.
- 16 Huqun IS, Miyazawa H, Ishii K, et al. Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. *Am J Respir Crit Care Med* 2007; 175: 263–268.
- 17 Saito A, Nikolaidis NM, Amlal H, et al. Modeling pulmonary alveolar microlithiasis by epithelial deletion of the Npt2b sodium phosphate cotransporter reveals putative biomarkers and strategies for treatment. *Sci Transl Med* 2015; 7: 313ra181.
- 18 Jönsson ÅLM, Bendstrup E, Mogensen S, et al. Eight novel variants in the SLC34A2 gene in pulmonary alveolar microlithiasis. *Eur Respir J* 2019; 55: 1900806.
- 19 Corut A, Senyigit A, Ugur SA, et al. Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. *Am J Hum Genet* 2006; 79: 650–656.
- 20 Ishihara Y, Hagiwara K, Zen K, et al. A case of pulmonary alveolar microlithiasis with an intragenetic deletion in SLC34A2 detected by a genome-wide SNP study. *Thorax* 2009; 64: 365–367.
- 21 Vismara MFM, Colao E, Fabiani F, et al. The sodium-phosphate co-transporter SLC34A2, and pulmonary alveolar microlithiasis: presentation of an inbred family and a novel truncating mutation in exon 3. *Respir Med Case Rep* 2015; 16: 77–80.
- 22 Mehta K, Dell S, Birken C, et al. pulmonary alveolar microlithiasis. *Can Respir J* 2016; 2016: 4938632.
- 23 Cakir E, Gedik AH, Özdemir A, et al. Response to disodium etidronate treatment in three siblings with pulmonary alveolar microlithiasis. *Respiration* 2015; 89: 583–586.
- 24 Özbudak IH, Başsorgun CI, Özbilim G, et al. Pulmonary alveolar microlithiasis with homozygous c.316G>C (p.G106R) mutation: a case report. *Türk Patoloji Derg* 2012; 28: 282–285.
- 25 Dandan S, Yuqin C, Wei L, et al. Novel deletion of SLC34A2 in Chinese patients of PAM shares mutation hot spot with fusion gene SLC34A2-ROS1 in lung cancer. *J Genet* 2018; 97: 939–944.
- 26 Simon CT, Lewis TC, Neemuchwala F, et al. Pulmonary alveolar microlithiasis: a case report with a novel mutation in the SLC78A9 gene and review of the literature. *Hum Pathol Case Rep* 2018; 13: 33–35.
- 27 Ma T, Ren J, Yin J, et al. A pedigree with pulmonary alveolar microlithiasis: a clinical case report and literature review. *Cell Biochem Biophys* 2014; 70: 565–572.
- 28 Gaber K, Najem S, Bader O BA. New mutation of SCL>A! Gene in a family with pulmonary alveolar microlithiasis in Libya. *Chest* 2012; 142: 439A.
- 29 Alastal A, Yamin H. Pulmonary alveolar microlithiasis caused by two homozygous mutations. *Am J Respir Crit Care Med* 2017; 195: A3438.
- 30 Yin X, Wang H, Wu D, et al. SLC34A2 Gene mutation of pulmonary alveolar microlithiasis: report of four cases and review of literatures. *Respir Med* 2013; 107: 217–222.
- 31 Zhong Y, Hu C, Cai X, et al. [A novel mutation of the SLC34A2 gene in a Chinese pedigree with pulmonary alveolar microlithiasis]. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2009; 26: 365–368.
- 32 Zhang D, Xiao K, Guan W, et al. An inbred family with pulmonary alveolar microlithiasis in China: a genome-wide SNP study. *Int J Clin Exp Pathol* 2017; 10: 446–452.
- 33 Ellison J. Novel human pathological mutations. Gene symbol: SLC34A2. Disease: pulmonary alveolar microlithiasis. *Hum Genet* 2009; 125: 333.
- 34 Jönsson ÅLM, Hilberg O, Bendstrup EM, et al. SLC34A2 gene mutation may explain comorbidity of pulmonary alveolar microlithiasis and aortic valve sclerosis. *Am J Respir Crit Care Med* 2012; 185: 464.
- 35 Proesmans M, Boon M, Verbeken E, et al. Pulmonary alveolar microlithiasis: a case report and review of the literature. *Eur J Pediatr* 2012; 171: 1069–1072.
- 36 Stokman L, Nossent EJ, Grunberg K, et al. A case of pulmonary alveolar microlithiasis associated with a homozygous 195 kb deletion encompassing the entire SLC34A2 gene. *Clin Case Rep* 2016; 4: 412–415.
- 37 Wang H, Yin X, Wu D, et al. SLC34A2 gene compound heterozygous mutation identification in a patient with pulmonary alveolar microlithiasis and computational 3D protein structure prediction. *Meta Gene* 2014; 2: 557–564.
- 38 Izumi H, Kurai J, Kodani M, et al. A novel SLC34A2 mutation in a patient with pulmonary alveolar microlithiasis. *Hum Genome Var* 2017; 4: 1–3.
- 39 Saito A, McCormack FX. Pulmonary alveolar microlithiasis. *Clin Chest Med* 2016; 37: 441–448.
- 40 Jönsson ÅLM, Simonsen U, Hilberg S, et al. Pulmonary alveolar microlithiasis: two case reports and review of the literature. *Eur Respir Rev* 2012; 21: 249–256.

- 41 Rea G, Sperandeo M, Sorrentino N, *et al.* Chest ultrasound findings in pulmonary alveolar microlithiasis. *J Med Ultrason* 2015; 42: 591–594.
- 42 Mariotta S, Guidi L, Mattia P, *et al.* Pulmonary Microlithiasis. *Respiration* 1997; 64: 165–169.
- 43 Millqvist E, Bende M. Capsaicin cough sensitivity is decreased in smokers. *Respir Med* 2001; 95: 19–21.
- 44 Sahoo MK, Karunanithi S, Bal CS. Pulmonary alveolar microlithiasis: imaging characteristics of planar and SPECT/CT bone scan versus 18F-FDG and 18F-sodium fluoride PET/CT scanning. *Jpn J Radiol* 2013; 31: 766–769.
- 45 Basu S, Shah M, Joshi JM, *et al.* Imaging calcific concretions of pulmonary alveolar microlithiasis with PET: insight into disease pathophysiology. *Clin Nucl Med* 2012; 37: 707–708.
- 46 Shah M, Joshi JM. Bone scintigraphy in pulmonary alveolar microlithiasis. *Indian J Chest Dis Allied Sci* 2011; 53: 221–223.
- 47 Günay E, Özcan A, Günay S, *et al.* Pulmonary alveolar microlithiasis with low fluorodeoxyglucose accumulation in PET/computed tomography. *Ann Thorac Med* 2011; 6: 237–240.
- 48 Ito K, Kubota K, Yukihiro M, *et al.* FDG-PET/CT finding of high uptake in pulmonary alveolar microlithiasis. *Ann Nucl Med* 2007; 21: 415–418.
- 49 Johansson KA, Marcoux VS, Ronksley PE, *et al.* Diagnostic yield and complications of transbronchial lung cryobiopsy for interstitial lung disease: A systematic review and metaanalysis. *Ann Am Thorac Soc* 2016; 13: 1828–1838.
- 50 Ravaglia C, Bonifazi M, Wells AU, *et al.* Safety and diagnostic yield of transbronchial lung cryobiopsy in diffuse parenchymal lung diseases: a comparative study versus video-assisted thoracoscopic lung biopsy and a systematic review of the literature. *Respiration* 2016; 91: 215–227.
- 51 Takahashi H, Chiba H, Shiratori M, *et al.* Elevated serum surfactant protein A and D in pulmonary alveolar microlithiasis. *Respirology* 2006; 11: 330–333.
- 52 Kuroki Y, Takahashi H, Chiba H, *et al.* Surfactant proteins A and D: disease markers. *Biochim Biophys Acta - Mol Basis Dis* 1998; 1408: 334–345.
- 53 Tao LC. Microliths in sputum specimens and their relationship to pulmonary alveolar microlithiasis. *Am J Clin Pathol* 1978; 69: 482–485.
- 54 Alkhankan E, Yamin H, Bukamur H, *et al.* Pulmonary alveolar microlithiasis diagnosed with radiography, CT, and bone scintigraphy. *Radiol Case Rep* 2019; 14: 775–777.
- 55 Gasparetto EL, Tazoniero P, Escuissato DL, *et al.* Pulmonary alveolar microlithiasis presenting with crazy-paving pattern on high resolution CT. *Br J Radiol* 2004; 77: 974–976.
- 56 Resorlu M, Toprak CA, Aylanc N, *et al.* Ultrasonography and computed tomography findings in pulmonary alveolar microlithiasis. *RoFo Fortschritte auf dem Gebiet der Röntgenstrahlen und der Bildgeb Verfahren* 2018; 190: 1063–1064.
- 57 Monabati A, Ghayumi MA, Kumar PV. Familial pulmonary alveolar microlithiasis diagnosed by bronchoalveolar lavage. A case report. *Acta Cytol* 2007; 51: 80–82.
- 58 Marchioril E, Souza AS, Franquet T, *et al.* Diffuse high-attenuation pulmonary abnormalities: a pattern-oriented diagnostic approach on high-resolution CT. *Am J Roentgenol* 2005; 184: 273–282.
- 59 Chan ED, Morales D V, Welsh CH, *et al.* Calcium deposition with or without bone formation in the lung. *Am J Respir Crit Care Med* 2002; 165: 1654–1669.
- 60 Feng Y, Zhao J, Yang Q, *et al.* Pulmonary melanoma and “crazy paving” patterns in chest images: A case report and literature review. *BMC Cancer* 2016; 16: 592.
- 61 Pracyk JB, Simonson SG, Young SL, *et al.* Composition of lung lavage in pulmonary alveolar microlithiasis. *Respiration* 1996; 63: 254–260.
- 62 Ganesan N, Ambroise MM, Ramdas A, *et al.* Pulmonary alveolar microlithiasis: an interesting case report with systematic review of Indian literature. *Front Med* 2015; 9: 229–238.
- 63 Flynn A, Agastayaraju AD. Pulmonary alveolar microlithiasis. *Int J Case Rep Images* 2013; 4: 108–110.
- 64 Taillé C, Debray MP, Danel C, *et al.* Calcium-solubilizing sodium thiosulfate failed to improve pulmonary alveolar microlithiasis: evaluation of calcium content with CT scan. *Respir Med Res* 2019; 75: 10–12.
- 65 Mascie-Taylor BH, Wardman AG, Madden CA, *et al.* A case of alveolar microlithiasis: observation over 22 years and recovery of material by lavage. *Thorax* 1985; 40: 952–953.
- 66 Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. *Mayo Clin Proc* 2008; 83: 1032–1045.
- 67 Russell RGG, Watts NB, Ebetino FH, *et al.* Mechanisms of action of bisphosphonates: similarit... [Osteoporos Int. 2008] - PubMed result. *Osteoporos Int* 2008; 19: 733–759.
- 68 Fleisch H. Bisphosphonates: mechanisms of action. *Endocr Rev Endocr Soc* 1998; 19: 80–100.
- 69 Jankovic S, Pavlov N, Ivkovic A, *et al.* Pulmonary alveolar microlithiasis in childhood: clinical and radiological follow-up. *Pediatr Pulmonol* 2002; 34: 384–387.
- 70 Özcelik U, Yalcin E, Ariyurek M, *et al.* Long-term results of disodium etidronate treatment in pulmonary alveolar microlithiasis. *Pediatr Pulmonol* 2010; 45: 514–517.
- 71 Özçelik U, Gülsün M, Göçmen A, *et al.* Treatment and follow-up of pulmonary alveolar microlithiasis with disodium editronate: radiological demonstration. *Pediatr Radiol* 2002; 32: 380–383.
- 72 Göçmen A, Toppare MF, Kiper N, *et al.* Treatment of pulmonary alveolar microlithiasis with a diphosphonate--preliminary results of a case. *Respiration* 1992; 59: 250–252.
- 73 Emiralioğlu N, Beken B, Özcan HN, *et al.* Diagnosis and treatment of pulmonary alveolar microlithiasis. *Pediatr Int* 2016; 58: 805–807.
- 74 Azim S, Azim W, Hayat F, *et al.* Treatment of pulmonary alveolar microlithiasis with allendronate sodium. *Biomedica* 2004; 20: 32.
- 75 Alrossais NM, Alshammari AM, Alrayes AM, *et al.* Pulmonary hypertension and polycythemia secondary to pulmonary alveolar microlithiasis treated with sequential bilateral lung transplant: a case study and literature review. *Am J Case Rep* 2019; 20: 1114–1119.
- 76 Jackson KB, Modry DL, Halenar J, *et al.* Single lung transplantation for pulmonary alveolar microlithiasis. *J Heart Lung Transplant* 2001; 20: 226.
- 77 Tachibana T, Hagiwara K, Johkoh T. Pulmonary alveolar microlithiasis: review and management. *Curr Opin Pulm Med* 2009; 15: 486–490.
- 78 Chinachoti N, Tangchai P. Pulmonary alveolar microlithiasis associated with the inhalation of snuff in Thailand. *Dis Chest* 1957; 32: 687–689.